Form 4 for TRVI Trevi Therapeutics, Inc.
Accepted 2024-12-17 00:00:00 ET · period of report 2024-12-13 · accession 0000950170-24-137255 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-12-17 | 2024-12-13 | TRVI | Galletta Christopher | See Remarks | M - OptEx | $0.51 | +15.0K | 19.9K | +304% | +$7,650 |
| D | 2024-12-17 | 2024-12-13 | TRVI | Galletta Christopher | See Remarks | M - OptEx | $0.00 | -15.0K | 20.0K | -43% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-13 | M | A | 15,000 | $0.51 | 19,935 | D | — | — | (F1) Includes 4,935 shares purchased through the Issuer's employee stock purchase plan. |
| 2 | Derivative | Stock Option (right to buy) | 2024-12-13 | M | D | 15,000 | $0.00 | 20,000 | D | $0.51 · — to 2032-02-10 | 15,000 Common Stock | (F2) This option was granted on February 11, 2022. The 35,000 shares of common stock underlying the option vested as to 25% of the shares on February 11, 2023 and vest as to the remaining 75% of the shares in equal monthly installments thereafter through February 11, 2026. |